Overview of Dr. Mauro
Dr. Michael Mauro is a hematologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from Geisel School of Medicine at Dartmouth and has been in practice 23 years. He is experienced in healthcare outcomes research, bcr-abl positive chronic myelogenous leukemia, antineoplastic agents, bcr-abl fusion proteins, and chromosome aberrations.
Office
225 Summit Avenue
Montvale, NJ 07645
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1997 - 2000
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1994 - 1997
- Geisel School of Medicine at DartmouthClass of 1994
Certifications & Licensure
- FL State Medical License 2021 - Present
- OR State Medical License 2000 - Present
- NJ State Medical License 2018 - 2025
- NH State Medical License 2024 - 2024
- NY State Medical License 1996 - 2024
- NC State Medical License 2020 - 2022
- ME State Medical License 2020 - 2021
- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia Start of enrollment: 2008 May 01
- Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML Start of enrollment: 2008 Aug 14
- A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL Start of enrollment: 2014 Apr 24
Publications & Presentations
PubMed
- 84 citationsClinical features of pulmonary arterial hypertension in patients receiving dasatinibNeil P. Shah, Nicola Wallis, Harrison W. Farber, Michael J. Mauro, Robert Wolf
American Journal of Hematology. 2015-11-01 - 66 citationsDefining and Managing Imatinib ResistanceMichael J. Mauro
Hematology. American Society of Hematology. Education Program. 2006-01-01 - 159 citationsRates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase ...Francis J. Giles, Michael J. Mauro, Frank Hong, Christine-Elke Ortmann, C. McNeill
Leukemia. 2013-06-01
Abstracts/Posters
- Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid LeukemiaMichael J. Mauro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloi...Michael J. Mauro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II StudyMichael J. Mauro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously t...2019 ASCO Annual Meeting - 6/1/2019
- Dosing Patterns of Dasatinib Use in Simplicity, an Observational Study in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients (pts) in Routine Clinical Practice2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Cardiovascular Mortality Among CML Patients in the Pre-TKI and TKI Eras: A SEER Analysis 1992-20042018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Authored Content
- Efficacy and Safety Outcomes by Baseline Comorbidity and Age in Patients Newly Diagnosed with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Treated with Dasatinib or Imatinib in DASISIONOctober 2017
Press Mentions
- Molecular Monitoring Deficient in Older Adults with CMLMay 2nd, 2023
- Comparing Asciminib with Bosutinib in Patients with Chronic-Phase Chronic Myeloid LeukemiaDecember 17th, 2021
- Do Additional Chromosomal Abnormalities Noted at CML Diagnosis Affect Response and Survival?November 16th, 2017
- Join now to see all
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Massachusetts Blue Care Elect PPO
CIGNA Open Access
CIGNA PPO
First Choice
First Health PPO
Great West PPO
Health Net Oregon PPOHumana ChoiceCare Network PPO
Lifewise Health Plan of Oregon
Multiplan PHCS PPO
Multiplan PPO
ODS Network
Pacificare HMO
PacificSource Preferred PSN
Providence Health System Preferred PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: